Increased DNA damage in progression of COPD: a response by poly(ADP-ribose) polymerase-1

PLoS One. 2013 Jul 24;8(7):e70333. doi: 10.1371/journal.pone.0070333. Print 2013.

Abstract

Chronic oxidative stress (OS), a major mechanism of chronic obstructive pulmonary disease (COPD), may cause significant damage to DNA. Poly(ADP-ribose) polymerase (PARP)-1 is rapidly activated by OS-induced DNA lesions. However, the degree of DNA damage along with the evolution of COPD is unclear. In peripheral blood mononuclear cells of non-smoking individuals, non-obstructive smokers, patients with COPD of all stages and those with COPD exacerbation, we evaluated DNA damage, PARP activity and PARP-1 mRNA expression using Comet Assay IV, biotinylated-NAD incorporation assay and qRT-PCR, respectively and subjected results to ordinal logistic regression modelling. Adjusted for demographics, smoking-related parameters and lung function, novel comet parameters, tail length/cell length ratio and tail migration/cell length ratio, showed the greatest increase along the study groups corresponding to the evolution of COPD [odds ratio (OR) 7.88, 95% CI 4.26-14.57; p<0.001 and OR 3.91, 95% CI 2.69-5.66; p<0.001, respectively]. Analogously, PARP activity increased significantly over the groups (OR = 1.01; 95%; p<0.001). An antioxidant tetrapeptide UPF17 significantly reduced the PARP-1 mRNA expression in COPD, compared to that in non-obstructive individuals (p = 0.040). Tail length/cell length and tail migration/cell length ratios provide novel progression-sensitive tools for assessment of DNA damage. However, it remains to be elucidated whether inhibition of an elevated PARP-1 activity has a safe enough potential to break the vicious cycle of the development and progression of COPD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Comet Assay
  • DNA Damage / genetics*
  • Female
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Male
  • Middle Aged
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases / metabolism*
  • Pulmonary Disease, Chronic Obstructive / genetics*

Substances

  • PARP1 protein, human
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases

Grants and funding

This study was funded with grants No. 7856, 9043 and 6566 from the Estonian Science Foundation, by targeted financing PARBK 0906 from the University of Tartu, by targeted financing from Ministry of Education and Science of Estonia (SF0180105s08) and by the European Union through the European Regional Development. The work was also supported by The Hungarian Scientific Research Fund (K73003, K60780 and K82009) and Hungarian Social Renewal Operational Programme (4.2.2-08/1-2008-0019; 4.2.1./B-09/1/KONV-2010-0007 and 4.2.2.A-111/1/KONV-2012-0025). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.